Prosonix signs particle technology agreement with University of Bath
Prosonix, of Oxford, UK has signed an agreement with the University of Bath for the exclusive commercialisation of the University's sonocrystallisation particle engineering technology Solution Atomisation and Crystallisation by Sonication (SAXTM).
Prosonix, of Oxford, UK has signed an agreement with the University of Bath for the exclusive commercialisation of the University's sonocrystallisation particle engineering technology Solution Atomisation and Crystallisation by Sonication (SAXTM).
The agreement builds on 18 months of initial collaboration and technology evaluation between the parties.
Discovered by Dr Robert Price from the University's department of pharmacy and pharmacology SAXTM is a single step, solution-to-particle-technology, incorporating solution atomisation and sonocrystallisation, that has shown significant potential benefits in the production of particles.
The benefits have been evident in inhaled therapeutics particularly, but also have tremendous potential in production of nanosuspensions and improved particles for other formulation techniques, including pharmaceutical co-crystals and combination based therapies, Prosonix says.
SAXTM particles can have unique spherical shape and surface nanotopology providing minimum area for interfacial contact with low surface free energies.
Prosonix ceo David Hipkiss said, 'We believe the SAXTM technology has world beating potential in allowing pharmaceutical companies to engineer particles 'to order' with the optimum crystal morphology, polymorph control and formulation performance.'